In January 2010 BÜHLMANN starts the distribution of the innovative diagnostic products of BioPorto in Switzerland , Austria and France . The main product of BioPorto is the NGAL ELISA which is the most important biomarker for direct diagnosis of acute kidney injury (AKI).

NGAL begins to rise within an hour of AKI, whereas current diagnostic methods only detect the consequences of damage well after the event.

The NGAL product portfolio of BioPorto contains a rapid CE marked ELISA allowing a raised level of NGAL to be rapidly determined in urine or plasma sample. For research samples the slower but more sensitive ELISA is to be preferred. For pharmaceutical animal research BioPorto is offering three different ELISA variants for mouse, rat or dog samples.

Besides the Cystatin C assay for accurate diagnosis of chronic kidney disease (CKD), BÜHLMANN now offers this remarkable addition for AKI complementing the kidney disease portfolio.